Andy Porter is director of the Scottish Biologics Facility and the CTO of biologics company Elasmogen. Porter was the founder and CSO of Haptogen. In 2005 he was the Ernst and Young UK Science and Technology Entrepreneur of the Year. He is a Fellow of the Royal Society of Edinburgh and of the Royal Society of Biology. He has been on the board of NovaBiotics since 2009. NovaBiotics has announced the successful completion of its phase 2b cystic fibrosis trial for Lynovex and was EuropaBio’s 2017 ‘most innovative SME’.